08/04/2005 (Agence Europe) - The European Medicines Agency announced on 7 April that the American laboratory Pfizer has accepted the “suspension of use” of Bextra, which contains an active ingredient known as valdecoxib which belongs to the COX-2 group of inhibitors, the assessment of which began at the end of 2004 in London following the withdrawal of Vioxx, but has not yet been completed. This interim measure has been taken in Europe following a similar decision in the USA at the...